Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients

被引:4
作者
Kapoor, Amit [1 ,2 ]
Shapiro, Beth [3 ]
Shafer, Robert W. [4 ]
Shulman, Nancy [4 ]
Rhee, Soo-Yon [4 ]
Delwart, Eric L. [1 ,2 ]
机构
[1] Blood Syst Res Inst, San Francisco, CA 94118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Univ Oxford, Dept Zool, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England
[4] Stanford Univ, Med Ctr, Dept Med, Div Infect Dis, Stanford, CA 94305 USA
关键词
D O I
10.1186/1742-4690-5-7
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Combination anti-viral therapies have reduced treatment failure rates by requiring multiple specific mutations to be selected on the same viral genome to impart high-level drug resistance. To determine if the common protease inhibitor resistance mutation L90M is only selected once or repeatedly on different HIV genetic backbones during the course of failed antiviral therapies we analyzed a linked region of the viral genome during the evolution of multi-drug resistance. Results: Using L90M allele specific PCR we amplified and sequenced gag-pro regions linked to very early L90M containing HIV variants prior to their emergence and detection as dominant viruses in 15 failed salvage therapy patients. The early minority L90M linked sequences were then compared to those of the later L90M viruses that came to dominate the plasma quasispecies. Using Bayesian evolutionary analysis sampling trees the emergence of L90M containing viruses was seen to take place on multiple occasion in 5 patients, only once for 2 patients and an undetermined number of time for the remaining 8 patients. Conclusion: These results indicate that early L90M mutants can frequently be displaced by viruses carrying independently selected L90M mutations rather than by descendents of the earlier mutants.
引用
收藏
页数:9
相关论文
共 37 条
[1]   Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: Clinical significance and implications for resistance to protease inhibitors [J].
Bally, F ;
Martinez, R ;
Peters, S ;
Sudre, P ;
Telenti, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (13) :1209-1213
[2]   Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults [J].
Barbour, JD ;
Wrin, T ;
Grant, RM ;
Martin, JN ;
Segal, MR ;
Petropoulos, CJ ;
Deeks, SG .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11104-11112
[3]   Natural variation in HIV-1 protease, gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1 [J].
Barrie, KA ;
Perez, E ;
Lamers, SL ;
Farmerie, WG ;
Dunn, BM ;
Sleasman, JW ;
Goodenow, MM .
VIROLOGY, 1996, 219 (02) :407-416
[4]   Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug [J].
Borman, AM ;
Paulous, S ;
Clavel, F .
JOURNAL OF GENERAL VIROLOGY, 1996, 77 :419-426
[5]   A simple and robust statistical test for detecting the presence of recombination [J].
Bruen, TC ;
Philippe, H ;
Bryant, D .
GENETICS, 2006, 172 (04) :2665-2681
[6]   Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients [J].
Charpentier, C ;
Nora, T ;
Tenaillon, O ;
Clavel, F ;
Hance, AJ .
JOURNAL OF VIROLOGY, 2006, 80 (05) :2472-2482
[7]   Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors [J].
Charpentier, C ;
Dwyer, DE ;
Mammano, F ;
Lecossier, D ;
Clavel, F ;
Hance, AJ .
JOURNAL OF VIROLOGY, 2004, 78 (08) :4234-4247
[8]  
Coffin JM, 1996, AIDS, V10, pS75
[9]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[10]   Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor [J].
Condra, JH ;
Holder, DJ ;
Schleif, WA ;
Blahy, OM ;
Danovich, RM ;
Gabryelski, LJ ;
Graham, DJ ;
Laird, D ;
Quintero, JC ;
Rhodes, A ;
Robbins, HL ;
Roth, E ;
Shivaprakash, M ;
Yang, T ;
Chodakewitz, JA ;
Deutsch, PJ ;
Leavitt, RY ;
Massari, FE ;
Mellors, JW ;
Squires, KE ;
Steigbigel, RT ;
Teppler, H ;
Emini, EA .
JOURNAL OF VIROLOGY, 1996, 70 (12) :8270-8276